STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Servier announced it will acquire Edgewise Therapeutics' muscular dystrophy business in a deal worth up to $2.65 billion.
- Edgewise Therapeutics' lead drug sevasemten is being studied in a pivotal Becker muscular dystrophy trial and a Phase 2 Duchenne muscular dystrophy trial.
- Sevasemten is an oral therapy designed to protect muscles from damage in both rare dystrophies.
- Deal includes an upfront payment of $1.55 billion and potential milestone payments of up to $1.1 billion.
Why it matters: Servier secures a late‑stage muscular dystrophy candidate, expanding its rare‑disease pipeline, while Edgewise’s shareholders receive $1.55 billion upfront and stand to earn up to $1.1 billion in milestones, accelerating development of sevasemten for Becker and Duchenne patients.
